These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14767715)

  • 1. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile.
    Bartoszyk GD; Van Amsterdam C; Greiner HE; Rautenberg W; Russ H; Seyfried CA
    J Neural Transm (Vienna); 2004 Feb; 111(2):113-26. PubMed ID: 14767715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
    Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
    Kuzhikandathil EV; Bartoszyk GD
    Neuropharmacology; 2006 Sep; 51(4):873-84. PubMed ID: 16844149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
    Bibbiani F; Oh JD; Chase TN
    Neurology; 2001 Nov; 57(10):1829-34. PubMed ID: 11723272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
    Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
    Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
    Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
    Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.
    Ye N; Song Z; Zhang A
    Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.